Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of only 10%. It is estimated that over 57,000 people will be diagnosed with pancreatic cancer in the United States in 2020, and over 47,000 will die from the disease. However, recent research has shown that combining two chemotherapy drugs, AMP945 and FOLFIRINOX, may improve treatment outcomes for patients with pancreatic cancer.
According to a recent article published on Drugs.com MedNews, a study conducted by researchers at the University of Texas MD Anderson Cancer Center found that combining AMP945 with FOLFIRINOX improved treatment outcomes in a pancreatic cancer model. The study was published in the journal Cancer Research.
AMP945 is a novel small molecule inhibitor that targets the protein kinase CK2, which is overexpressed in many types of cancer, including pancreatic cancer. FOLFIRINOX is a combination of four chemotherapy drugs: 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin. It is currently the standard of care for patients with advanced pancreatic cancer.
The study found that combining AMP945 with FOLFIRINOX resulted in a significant reduction in tumor growth and an increase in survival compared to treatment with FOLFIRINOX alone. The combination therapy also reduced the number of cancer stem cells, which are thought to be responsible for tumor recurrence and resistance to chemotherapy.
The researchers believe that the combination of AMP945 and FOLFIRINOX works by targeting different pathways involved in cancer growth and progression. AMP945 targets CK2, which is involved in cell proliferation and survival, while FOLFIRINOX targets DNA synthesis and repair.
The study is still in the preclinical stage, and further research is needed to determine if the combination therapy will be effective in humans. However, the results are promising and suggest that combining AMP945 with FOLFIRINOX may be a viable treatment option for patients with pancreatic cancer.
Pancreatic cancer is a challenging disease to treat, and new treatment options are desperately needed. The combination of AMP945 and FOLFIRINOX offers hope for patients with this devastating disease. As research continues, it is hoped that this combination therapy will prove to be an effective treatment option for patients with pancreatic cancer.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Minting the Future w Adryenn Ashley. Access Here.
- Buy and Sell Shares in PRE-IPO Companies with PREIPO®. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: https://platohealth.ai/amp945-combined-with-folfirinox-enhances-treatment-effects-in-model-of-pancreatic-cancer-drugs-com-mednews/